Source comparison
Drug Affinity Complex CJC vs CJC-1295: Structural Comparison
Molecular Structure Modified GRF 1-29 + Drug Affinity Complex linker at Lys15 Modified GRF 1-29 (amino acids 1–29 of hGHRH with substitutions at positions 2, 8, 15, 27) DAC adds a 600 Da conjugate that fundamentally alters pharmacokinetics Plasma Half-Life 6–8
This comparison does not assign a generated winner or score.
- Molecular Structure
- Modified GRF 1-29 + Drug Affinity Complex linker at Lys15
- Modified GRF 1-29 (amino acids 1–29 of hGHRH with substitutions at positions 2, 8, 15, 27)
- DAC adds a 600 Da conjugate that fundamentally alters pharmacokinetics
- Plasma Half-Life
- 6–8 days
- 30–60 minutes
- Half-life difference determines whether daily or weekly dosing is required
- Mechanism of Persistence
- Binds serum albumin via DAC moiety, reducing renal clearance and enzymatic degradation
- Rapid clearance. No albumin binding, susceptible to DPP-IV cleavage
- Albumin binding is the key protective mechanism
- Dosing Frequency (Research Protocols)
- Once or twice weekly
- 2–3 times daily
- Frequency impacts study feasibility and compliance
- GH Release Profile
- Sustained elevation in baseline GH over 5–7 days
- Acute pulse lasting 2–4 hours post-injection
- Profile type determines which research questions each analog can address
- Regulatory Status
- Not FDA-approved; available for research use only
- Both are research-grade peptides. Neither is an approved therapeutic